1048 related articles for article (PubMed ID: 7682320)
21. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.
Wolfberg AJ; Growdon WB; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
Obstet Gynecol; 2006 Aug; 108(2):393-6. PubMed ID: 16880311
[TBL] [Abstract][Full Text] [Related]
22. A rapid solid-phase radioimmunoassay specific for human chorionic gonadotropin in gestational trophoblastic disease.
Goldstein DP; Pastorfide GB; Osathanondh R; Kosasa TS
Obstet Gynecol; 1975 May; 45(5):527-30. PubMed ID: 164644
[TBL] [Abstract][Full Text] [Related]
23. First trimester diagnosis of partial mole.
Phupong V; Triratanachat S; Promchainant C; Ultchaswadi P
Arch Gynecol Obstet; 2005 Sep; 272(3):235-7. PubMed ID: 15875207
[TBL] [Abstract][Full Text] [Related]
24. The natural history of theca lutein cysts.
Montz FJ; Schlaerth JB; Morrow CP
Obstet Gynecol; 1988 Aug; 72(2):247-51. PubMed ID: 2455880
[TBL] [Abstract][Full Text] [Related]
25. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
[TBL] [Abstract][Full Text] [Related]
26. Partial hydatidiform mole with false-negative urine human chorionic gonadatropin test in the emergency department.
Mundangepfupfu T; Waseem M
J Emerg Med; 2014 Mar; 46(3):348-50. PubMed ID: 24188605
[TBL] [Abstract][Full Text] [Related]
27. Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy.
Schlaerth JB; Morrow CP; Kletzky OA; Nalick RH; D'Ablaing GA
Obstet Gynecol; 1981 Oct; 58(4):478-82. PubMed ID: 7279342
[TBL] [Abstract][Full Text] [Related]
28. Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy.
Van Trommel NE; Sweep FC; Ross HA; Massuger LF; Thomas CM
Int J Mol Med; 2006 Oct; 18(4):705-11. PubMed ID: 16964426
[TBL] [Abstract][Full Text] [Related]
29. Recurrent gestational trophoblastic disease in a case of suspected quiescent gestational trophoblastic disease: a case report.
Sasaki S; Sasaki Y; Iino K
J Reprod Med; 2010; 55(7-8):317-20. PubMed ID: 20795345
[TBL] [Abstract][Full Text] [Related]
30. Human chorionic gonadotropin and free subunits' serum levels in patients with partial and complete hydatidiform moles.
Berkowitz R; Ozturk M; Goldstein D; Bernstein M; Hill L; Wands JR
Obstet Gynecol; 1989 Aug; 74(2):212-6. PubMed ID: 2473429
[TBL] [Abstract][Full Text] [Related]
31. Analysis of risk factors for persistent gestational trophoblastic disease.
Khoo SK; Baartz D; Sidhu M; Yip WL; Tripcony L
Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):657-9. PubMed ID: 20070718
[TBL] [Abstract][Full Text] [Related]
32. Serum human chorionic gonadotropin regression pattern in persistent trophoblastic disease during chemotherapy.
Lertkhachonsuk R; Limpongsanurak S
J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S352-9. PubMed ID: 11529357
[TBL] [Abstract][Full Text] [Related]
33. Serum SP1, hPL and beta-hCG levels in trophoblastic diseases.
Zhang WY; Yen GL
Chin Med J (Engl); 1991 Dec; 104(12):995-8. PubMed ID: 1723674
[TBL] [Abstract][Full Text] [Related]
34. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
[TBL] [Abstract][Full Text] [Related]
35. A model for the behavior of beta-hCG after evacuation of hydatidiform moles.
Schoeberl MR
Gynecol Oncol; 2007 Jun; 105(3):776-9. PubMed ID: 17395254
[TBL] [Abstract][Full Text] [Related]
36. Current approaches to diagnosis and treatment of gestational trophoblastic disease.
Smith DB; O'Reilly SM; Newlands ES
Curr Opin Obstet Gynecol; 1993 Feb; 5(1):84-91. PubMed ID: 8381037
[TBL] [Abstract][Full Text] [Related]
37. [Gestational trophoblastic disease. A 6-year experience at the Instituto Nacional de Perinatología].
Lira Plascencia J; Tenorio González F; Gomezpedroso Rea J; Novoa Vargas A; Aranda Flores C; Ibargüengoitia Ochoa F
Ginecol Obstet Mex; 1995 Nov; 63():478-82. PubMed ID: 8537038
[TBL] [Abstract][Full Text] [Related]
38. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
[TBL] [Abstract][Full Text] [Related]
39. Intraplacental choriocarcinoma arising in a second trimester placenta with partial hydatidiform mole.
Medeiros F; Callahan MJ; Elvin JA; Dorfman DM; Berkowitz RS; Quade BJ
Int J Gynecol Pathol; 2008 Apr; 27(2):247-51. PubMed ID: 18317216
[TBL] [Abstract][Full Text] [Related]
40. Complete hydatidiform mole in women aged 40 to 49 years.
Elias KM; Shoni M; Bernstein M; Goldstein DP; Berkowitz RS
J Reprod Med; 2012; 57(5-6):254-8. PubMed ID: 22696822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
